{"entity":{"id":"xnw27011","kind":"drug","name":"XNW27011","aka":[],"tldr":"XNW27011 is an experimental antibody-drug conjugate from Astellas Pharma Global Development in phase 2 trials for pancreatic ductal adenocarcinoma, non-small-cell lung cancer and ovarian cancer, aimed at Claudin 18.2.","summary":"XNW27011 is an antibody-drug conjugate developed by Astellas Pharma Global Development. Its target is Claudin 18.2 (the sponsor names Claudin 18.2 (CLDN18.2)). The sponsor states: XNW27011 is an antibody-drug conjugate targeting Claudin 18.2, a tight-junction transmembrane protein, carrying the topoisomerase I inhibitor payload YL0010014, given intravenously every three weeks. ClinicalTrials.gov describes the intervention as: Eligible patient(s) in each dose cohort will receive the assigned XNW27011 dose administration every 3 weeks (Q3W, cycle) until intolerable toxicity, progression of the disease without clinical benefit, or withdrawal of informed consent. An. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in pancreatic ductal adenocarcinoma, non-small-cell lung cancer, ovarian cancer, colorectal cancer and biliary tract cancer. The largest, NCT06792435, plans to enrol 240 participants with primary completion expected 2026-12-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of XNW27011","url":"https://clinicaltrials.gov/search?intr=XNW27011"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic","nsclc","ovarian","colorectal","cholangiocarcinoma","gastric"],"sections":[],"technologies":[],"targets":["cldn18-2"],"drugs":[],"companies":["astellas"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06792435"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"ADC","payload":"YL0010014 (topoisomerase I inhibitor), as stated in the registry record; DAR not stated","mechanism":"XNW27011 is an antibody-drug conjugate targeting Claudin 18.2, a tight-junction transmembrane protein, carrying the topoisomerase I inhibitor payload YL0010014, given intravenously every three weeks.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/xnw27011/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/"}],"company":[{"id":"astellas","kind":"company","name":"Astellas","route":"/companies/astellas/"}],"trial":[{"id":"nct06792435","kind":"trial","name":"XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.","route":"/trials/nct06792435/"}]}}